Investors & Media

Press Releases

Keyword Search

Dec
20
2024
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Dec
03
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec
03
2024
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
Dec
02
2024
Cytokinetics to Participate in December Investor Conferences
Dec
02
2024
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Nov
19
2024
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Nov
16
2024
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
Nov
16
2024
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
Nov
12
2024
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
Nov
11
2024
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
Nov
06
2024
Cytokinetics Reports Third Quarter 2024 Financial Results
Nov
05
2024
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024
Nov
04
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct
23
2024
Cytokinetics to Announce Third Quarter Results on November 6, 2024
Oct
16
2024
Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
Oct
03
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct
02
2024
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
Sep
30
2024
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
Sep
27
2024
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
Sep
24
2024
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Sep
19
2024
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
Sep
09
2024
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
Sep
05
2024
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
Sep
04
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep
01
2024
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
Sep
01
2024
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Aug
29
2024
Cytokinetics to Participate in September Investor Conferences
Aug
08
2024
Cytokinetics Reports Second Quarter 2024 Financial Results
Aug
01
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jul
30
2024
Cytokinetics Announces Call for Proposals for Corporate Giving Program
Jul
25
2024
Cytokinetics to Announce Second Quarter Results on August 8, 2024
Jul
16
2024
Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
Jul
03
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jun
17
2024
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
Jun
04
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May
29
2024
Cytokinetics to Participate in June Investor Conferences
May
28
2024
Cytokinetics Announces Closing of Public Offering of Common Stock
May
22
2024
Cytokinetics Announces Pricing of Public Offering of Common Stock
May
22
2024
Cytokinetics Announces Proposed Public Offering of Common Stock
May
22
2024
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May
17
2024
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
May
15
2024
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
May
13
2024
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
May
13
2024
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
May
08
2024
Cytokinetics Reports First Quarter 2024 Financial Results
May
08
2024
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
May
08
2024
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
May
07
2024
Cytokinetics to Hold Annual Meeting of Stockholders
May
02
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr
29
2024
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Apr
24
2024
Cytokinetics to Announce First Quarter Results on May 8, 2024
Apr
10
2024
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Apr
05
2024
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
Apr
02
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr
01
2024
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Mar
25
2024
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
Mar
04
2024
Cytokinetics to Participate in March Investor Conferences
Mar
01
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb
29
2024
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
Feb
28
2024
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
Feb
27
2024
Cytokinetics Reports Fourth Quarter 2023 Financial Results
Feb
13
2024
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
Feb
06
2024
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan
29
2024
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
Jan
25
2024
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
Jan
18
2024
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
Jan
03
2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan
02
2024
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

More Resources